CD8+CD103+ Tumor–Infiltrating Lymphocytes Are Tumor-Specific Tissue-Resident Memory T Cells and a Prognostic Factor for Survival in Lung Cancer Patients
The DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.
Abstract
We had previously demonstrated the role of CD103 integrin on lung tumor-infiltrating lymphocyte (TIL) clones in promoting specific TCR-mediated epithelial tumor cell cytotoxicity. However, the contribution of CD103 on intratumoral T cell distribution and functions and the prognosis significance of TIL subpopulations in non–small cell lung carcinoma (NSCLC) have thus far not been systematically addressed. In this study, we show that an enhanced CD103+ TIL subset correlates with improved early stage NSCLC patient survival and increased intraepithelial lymphocyte infiltration. Moreover, our results indicate that CD8+CD103+ TIL, freshly isolated from NSCLC specimens, display transcriptomic and phenotypic signatures characteristic of tissue-resident memory T cells and frequently express PD-1 and Tim-3 checkpoint receptors. This TIL subset also displays increased activation-induced cell death and mediates specific cytolytic activity toward autologous tumor cells upon blockade of the PD-1–PD-L1 interaction. These findings emphasize the role of CD8+CD103+ tissue-resident memory T cells in promoting intratumoral CTL responses and support the rationale for using anti–PD-1 blocking Ab to reverse tumor-induced T cell exhaustion in NSCLC patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Further research revealed that the presence of CD103+CD8+ TILs is a positive prognostic marker in several cancers [269-272].”
From Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition) (2021) · cites this paper as [270]
In the citing paper
“Previous studies demonstrated that enhanced CD8+CD103+ TRM TILs correlate with improved survival in patients with early stage NSCLC18 and with other types of cancer19.”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [18]
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · cited 1×
“types of advanced solid tumors, including NSCLC (43, 44).”
BackgroundTumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Munger, J. S., Huang, X., Kawakatsu, H., Griffiths, M. J. D., Dalton, S. L., Wu, J., Pittet, J.-F., Kaminski, N., Garat, C., Matthay, M. A., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)80545-0 · Cited by 2,076
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072 · cited 1×
“both molecules has been reported to transmit a death signal to T cells (40, 41).”
BackgroundUpregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction
Trautmann, L., Janbazian, L., Chomont, N., Said, E. A., Gimmig, S., Bessette, B., Boulassel, M.-R., Delwart, E., Sepulveda, H., Balderas, R. S., et al. (2006) · Nature Medicine · doi:10.1038/nm1482 · Cited by 1,565
The developmental pathway for CD103+CD8+ tissue-resident memory T cells of skin
Mackay, L. K., Rahimpour, A., Ma, J. Z., Collins, N., Stock, A. T., Hafon, M.-L., Vega-Ramos, J., Lauzurica, P., Mueller, S. N., Stefanovic, T., et al. (2013) · Nature Immunology · doi:10.1038/ni.2744 · Cited by 1,331 · cited 5×
“Indeed, downregulation of SIP1 was observed in CD103CD8 TRM T cells (18) and appeared to be required for their retention in peripheral tissues (28).”
BackgroundInfluentialFourcade, J., Sun, Z., Benallaoua, M., Guillaume, P., Luescher, I. F., Sander, C., Kirkwood, J. M., Kuchroo, V., & Zarour, H. M. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100637 · Cited by 1,307 · cited 1×
“Among these inhibitory receptors, CTLA-4, PD-1, and Tim3 appeared to be associated with T cell exhaustion in chronic viral infections (35–38) and tumor progression (39).”
BackgroundPD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
Gros, A., Robbins, P. F., Yao, X., Li, Y. F., Turcotte, S., Tran, E., Wunderlich, J. R., Mixon, A., Farid, S., Dudley, M. E., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73639 · Cited by 1,111 · cited 1×
“In the latter and present studies, CD103 T cells expressed high levels of PD-1, which has been defined as a biomarker of tumor-specific T cells (33).”
BackgroundSkin infection generates non-migratory memory CD8+ TRM cells providing global skin immunity
Jiang, X., Clark, R. A., Liu, L., Wagers, A. J., Fuhlbrigge, R. C., & Kupper, T. S. (2012) · Nature · doi:10.1038/nature10851 · Cited by 891 · cited 1×
“TRM T cells are highly activated T lymphocytes that reside within a variety of peripheral tissues, including intestine (17, 20), brain (21), skin (22, 23), and lung”
Background
Cited by
Items 601–661 of 661
Interplay between innate epithelial sensing and mucosal immunity
Scarfe, L. (2024) · University of Birmingham Institutional Research Archive (University of Birmingham)
Engineering agnostic modules for the tuning of CAR T cell \nfunction
Grothier, T. (2023) · UCL Discovery (University College London)
Prognostic significance of tissue-resident CD8+ T cells in breast cancer: an African population
Field, L. (2022) · Nottingham ePrints (University of Nottingham)
Brinkschmidt, T., Zielinski, C., & München, T. U. (2022) · mediaTUM (Technical University of Munich)
Pre-Existing Immunity Shapes Cancer Immunotherapy Efficacy
Xagara, A., Koinis, F., Tsapakidis, K., Samaras, I., Chantzara, E., Vasilieva, K., Lazarou, A., Georgoulias, V., & Kotsakis, A. P. (2026) · Onco · doi:10.3390/onco6010004
“Moreover, it is clear that high pre-existing levels of PD-1 or PD-L1 CD8 + T cells in TME [41,45,47,50–52] as well as in circulation [26,53–56] are correlated positively with survival benefit.”
Tumor-embedded Immunity and TRM Cell Functions in Cancer
Younas, K., Ali, A., Khatoon, A., Ullah, M., Akbar, K., & Noor, I. (2026) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/0113895575412480251114071338
Tuning tissue-resident memory T cells to fuel cancer immunotherapy
Zhang, Y., Fang, Y.-X., Xiao, Y., Li, S., & Sun, Z.-J. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.116308
Wang, C.-H. (2022) · TSpace (University of Toronto)
Chi, C.-C., Li, Z., Cai, S., & Tang, Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1760904
Tosun, M., & Schenerman, M. A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-21988-7.00028-1
Stephens, H. R., Elkins, E., Li, J., Swalley, Z. N., Ogbonna, H. N., Muri, P., Roberts, Z. J., Dempsey, F., Ali, M. A., Siam, M. H. B., et al. (2026) · The Journal of Immunology · doi:10.1093/jimmun/vkag013
Toma, B., Tanasa, M. P., & Danciu, M. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189580
Devi-Marulkar, P. (2015) · theses.fr (ABES) · doi:10.70675/1afef94czc6daz4936zb0d3z44f75d1762b1
Development of a cancer vaccine approach in lung cancer based on a new tumor antigen
Virk, Y. (2016) · theses.fr (ABES) · doi:10.70675/788c4c17z4a16z4b07zb1feza1875aee3060
Caractérisation des carcinomes sarcomatoïdes primitifs pulmonaires
Vieira, T. (2016) · theses.fr (ABES) · doi:10.70675/73602527ze62az4905zbcbcz8bde89ae8aa4
Gauthier, L. (2017) · theses.fr (ABES) · doi:10.70675/f7f72efczf2a3z49ffza23az89576223d33a
“, 1999), et dans les tumeurs épithéliales (Djenidi et al., 2015).”
BackgroundInfluentialTargeting the metabolic environment to modulate T cell effector function
Matias, M. I. (2019) · theses.fr (ABES) · doi:10.70675/0582ddaaze61dz4707z9cb1zdb8fe1d82653
Chraa, D. (2019) · theses.fr (ABES) · doi:10.70675/8ad0de1ezeb55z4983z9084z94cc8799b353
Immune biomarkers of the efficacy of checkpoint inhibitors in advanced lung cancer
Rochigneux, P. (2021) · theses.fr (ABES) · doi:10.70675/a681be3bz25eez4193z8df5za159cdd1666c
Weulersse, M. (2019) · theses.fr (ABES) · doi:10.70675/2a56dbcazd721z44daz9b18z27d6c10e6137
Jacquier, A. (2021) · theses.fr (ABES) · doi:10.70675/1f4a5d35z55fdz4c43zb9d9zc696dc04d24d
Mécanismes de l'immunothérapie épicutanée des allergies alimentaires
Laoubi, L. (2020) · theses.fr (ABES) · doi:10.70675/848d7714za7e9z43d9zacaez47cd7d35182d
Impact of respiratory viral infections on tumor progression in Non-Small-Cell Lung Carcinoma (NSCLC)
Angrini, M. (2021) · theses.fr (ABES) · doi:10.70675/9c027d88z3675z44adza870z1802353e674a · Cited by 2
Rôle des cellules myéloïdes suppressives dans les infections pulmonaires à Pseudomonas aeruginosa
Born-Bony, M. (2024) · theses.fr (ABES) · doi:10.70675/41183170z0b22z40c7zbd6cz776a4f32f4a1
Cibler les lymphocytes T dans les Leucémies Aiguës Myéloïdes (LAM) : illusion ou réalité ?
Aziez, L. (2024) · theses.fr (ABES) · doi:10.70675/7b091b1ez0760z4b87z901dzfa55d898be36
Castro, V. D. (2024) · theses.fr (ABES) · doi:10.70675/21fe1180zedcez41e6z84f6z171e779c807e
Immunologic profile after surgical pancreatectomy
Garnier, J. (2023) · theses.fr (ABES) · doi:10.70675/bc5b1b5bz94abz45eczb37dz731958b6494f
François, A. (2023) · theses.fr (ABES) · doi:10.70675/9de3f722zafc2z40a0za6e8z8f7c7cc0450b
Adimi, Y. (2025) · theses.fr (ABES) · doi:10.70675/f93fdc0az5f36z4bbdza55az8e312d9ecc0b
Matoba, D., Saito, T., Noda, T., Uemura, M., Ueyama, A., Wada, H., Doki, Y., & Eguchi, H. (2026) · Anticancer Research · doi:10.21873/anticanres.18125
Cho, B. K., Lim, S. M., Lee, S. H., Kim, D. K., Pardo, N., Prizant, H., Lawrence, Y. R., Al-Sakaff, N. J. A., Helms, H., Gayevskiy, V., et al. (2026) · Lung Cancer · doi:10.1016/j.lungcan.2026.109354
Djerroudi, L., Mhaidly, R., Kieffer, Y., Damei, I., Croizer, H., Selvarasa, V., Gentric, G., Fuhrmann, L., Goncalves, A., Caly, M., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-72844-4 · Cited by 2
Optimization of a liver Trm cell-inducing mRNA vaccine by reduction of type I interferon responsePreprint
Minnell, J. J., Ganley, M., Lee, A. R., Phabmixay, T., Farrand, K. J., Burn, O. K., Mamum, J. C., Lamb, E., Draper, S. L., Chan, S. T. S., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.07.723643
Done, R. J., Ahmid, O., Smith, M. J., Evans, D. G., Pathmanaban, O. N., Brough, D., & Couper, K. N. (2026) · Brain Communications · doi:10.1093/braincomms/fcag192
“113,114 Functionally, T RM exhibit a hybrid profile that integrates features of both T CM and T EM populations.”
Epigenomics and Metabolomics: Pioneering New Frontiers in Breast Cancer Research and Treatment
(2026) · Frontiers research topics · doi:10.3389/978-2-8325-8096-7
Schwartz, M. A., Lue, D., Mutaher, M., McNerney, M., Olajide, O., Mehta, A., Rowe, J. H., Park, R. J.-H., Malehmir, M., Dubrot, J., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.14.732162
Steffke, E. E., Latifi, L., Hana, T., Hara, A., Coombs, M., Spurgeon, J., McAuliffe, J., Almeida, V. P., Wicki, A., Malak, S. A., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.18.733241
Lin, P., Wang, J., Xie, W., Xiu, S., & Huang, X. (2026) · Medicine · doi:10.1097/md.0000000000049490
“[25] Tumor-infiltrating B lymphocytes improve the prognosis of patients with triple-negative breast cancer through B-cell receptor-driven activation, proliferation, and class switching.”
Chen, J. M., Zhou, M., Cao, W., Zhou, Z., He, X., Pu, X., Hao, X., Chen, S., Zhou, Y., Ma, J., et al. (2026) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-026-04485-x
“Mechanistically, CD103 ⁺ cytotoxic T lymphocytes (CTLs) are known to predict anti-PD-1 response in HCC [29], and CD103 ⁺ CD8 ⁺ T cells exert cytolytic activity upon PD-1/ PD-L1 blockade [30].”
Nakata, J., Nakamura, N., Motooka, D., Yokota, C., Hayashi, Y., Hirayama, R., Fujiki, F., Morimoto, S., Umehara, T., Nakajima, H., et al. (2026) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdag176
Ladányi, A., Fröhlich, G., Hegyi, B., Horváth, P., & Balatoni, T. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1886388
Spatial Treg niches and the therapeutic reprogramming of tumour tolerance in cancer
Bautista, J., Delgado, M. D. C., Viteri-Recalde, J., Benítez-Núñez, M., Ramírez-Sánchez, D., & López-Cortés, A. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1921036
“CD8 + CD103 + tumour-infiltrating lymphocytes with resident-memory characteristics have been associated with prolonged survival in NSCLC, high-grade serous ovarian cancer and breast cancer (Djenidi et al., 2015; Webb et al., 2014; Savas et al., 2018).”
Sex, Timing, and Outcomes of Curative-Intent Immunotherapy: A Systematic Review and Meta-Analysis
Hollinger, A.-M., Gerard, C. L., Andreas, V. J., Roa‐Díaz, Z. M., Gillessen, S., Michielin, O. A., Pless, M., Peters, S., Micheloud, C., Hayoz, S., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.32635
Yamashita, K., NAGASAKA, T., Abe, T., Adachi, Y., Ito, R., Tachibana, T., Takahashi, T., Kagiyama, H., Imai, M., Tsuneki, T., et al. (2026) · International Journal of Clinical Oncology · doi:10.1007/s10147-026-03182-0
“Across multiple solid tumors including colorectal cancer, abundance of CD103⁺CD8⁺ T cells has been associated with improved patient outcomes [21–23].”
Gallus, M., Khan, S. H., Zhao, A., Benway, H., Lu, J., Nejo, T., Watchmaker, P. B., & Okada, H. (2026) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-026-00944-8
Iseas, S., Golubicki, M., Lacunza, E., Prost, D. M., Bouchereau, S., Lahaie, C., Baba-Hamed, N., Raymond, É., Adam, J., & Abba, M. C. (2026) · Scientific Reports · doi:10.1038/s41598-026-70067-7
Self-citationCucchiara, V. (n.d.) · Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele
Maranou, E. (2026) · UTUPub (University of Turku)
Dóra, D., Krencz, I., Sebestyén, A. R., Szalai, F., Roskó, B., Kamel, Y., Mokánszki, B., Király, P., Gálffy, G., & Lohinai, Z. (2026) · Research Square · doi:10.21203/rs.3.rs-11025245/v1
Sambucci, M., Fenoglio, D., Ferrera, F., Camporesi, L., Lagazio, A., Borsellino, G., Battistini, L., & Filaci, G. (2026) · European Journal of Immunology · doi:10.1002/eji.70288
Mickens, K. L., & Jonsson, A. H. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1905956
Anderle, N., van der Moolen, M., Teufel, C., Weghofer, A., Spangenberger, C., Cipriano, M., & Loskill, P. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-16110-0.00001-7
Metadata
- Authors
- Djenidi, F., Adam, J., Goubar, A., Durgeau, A., Meurice, G., de Montpréville, V., Validire, P., Besse, B., & Mami-Chouaib, F.
- Affiliations
- Université Paris-Sud (FR)
- INSERM Unité 1186 , 94805 Villejuif ,
- Institute Mutualiste Montsouris (FR)
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-04-01
- Volume
- 194
- Issue
- 7
- Pages
- 3475-3486
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1895620535
- Cited by
- 622
- References
- 51
- Citations by year
- 2026: 34 · 2025: 61 · 2024: 51 · 2023: 55 · 2022: 63 · 2021: 81 · 2020: 72 · 2019: 70 · 2018: 66 · 2017: 27 · 2016: 28 · 2015: 13
- FWCI
- 19.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Institut Gustave-Roussy
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- tumor-infiltrating lymphocytes, tissue-resident memory T cells, non-small cell lung cancer, PD-1, TIM-3, immune checkpoint blockade, T cell exhaustion, intraepithelial lymphocytes, patient survival, prognostic factors, T cell cytotoxicity
- MeSH terms
- Hepatitis A Virus Cellular Receptor 2, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, Cytotoxicity, Immunologic, Female, Humans, Immunologic Memory, Lung Neoplasms, Lymphocyte Activation, Male, Membrane Proteins, Middle Aged, Neoplasm Staging, Organ Specificity, Prognosis, Risk Factors, Antigens, CD, Immunophenotyping, Lymphocytes, Tumor-Infiltrating, CD8 Antigens, Gene Expression Profiling, Integrin alpha Chains, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.